Latest Goodwin News & Updates
See the latest news and media coverage for Goodwin. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global law firm focused on key industries
goodwinlaw.com- Headquarters
- Boston, United States
- Founded year
- 1912
- Company type
- Partnership
- Number of employees
- 5,000–10,000
Last updated
Latest news about Goodwin
In short: Goodwin achieved top Q1 2026 M&A rankings and advised on multi-billion dollar life sciences deals, including Eli Lilly’s $7.8 billion acquisition.
Company announcements
-
Goodwin guides Dremio on acquisition by SAP
The Technology team advised Dremio on SAP SE's acquisition to integrate Dremio into SAP Business Data Cloud and HANA Cloud, enabling federated data access and AI-ready capabilities.
-
Goodwin advises Perfuse Therapeutics on $2.45 billion acquisition by Bayer
Bayer acquires full rights to PER-001, a Phase II drug for glaucoma and diabetic retinopathy, with $300 million upfront and milestone payments.
-
Goodwin congratulates Rise Companies Corp. on merger completion
The SEC-registered transaction merges seven eREITs into Fundrise eREIT, LLC, combining $900 million in assets. Partner David Roberts led the team.
-
Goodwin guides syndicate on Hemab Therapeutics’ $346.7M IPO
The Life Sciences and Capital Markets team advised underwriters including Goldman Sachs on the upsized offering of 19,262,500 shares at $18 each. Hemab develops therapies for blood coagulation disorders.
Media coverage
-
Baker McKenzie, Goodwin Advise on Bayer s $2.45B US Ophthalmology Deal | Law.com
Bayer has tapped Baker McKenzie for its $2.45 billion U.S. acquisition of Perfuse Therapeutics,...
-
Lawyers at M&A law firms among 30 charged by US in insider trading scheme
Nineteen people were arrested, including attorney Nicolo Nourafchan, who federal prosecutors in...
-
Goodwin Recruits Paul Rosie as Partner in Life Sciences Group
Paul Rosie joined Goodwin as a partner in its life sciences group in Boston, the firm announced Tuesday.
-
Sidley, Goodwin Lead $1.1B Take-Private Deal For Esperion - Law360
Biopharmaceutical company Esperion Therapeutics, advised by Goodwin Procter LLP, on Friday announced plans to go private after being bought by Sidley Austin LLP-led healthcare-focused investment...
Track Goodwin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore